Continuing the multiple sclerosis risk sharing scheme is unjustified.
McCabe
Christopher
C
Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds LS2 9PL. c.mccabe@leeds.ac.uk
Chilcott
Jim
J
Claxton
Karl
K
Tappenden
Paul
P
Cooper
Cindy
C
Roberts
Jennifer
J
Cooper
Nicola
N
Abrams
Keith
K
D003362:Cost-Benefit Analysis; D016527:Drug Costs; D000068717:Glatiramer Acetate; D006297:Health Services Accessibility / Q000191:economics / Q000458:organization & administration*; D006801:Humans; D007372:Interferons / Q000191:economics / Q000600:supply & distribution; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000191:economics; D010455:Peptides / Q000191:economics / Q000600:supply & distribution; D019057:Quality-Adjusted Life Years; D020414:Risk Sharing, Financial; D013222:State Medicine / Q000191:economics
D010455:Peptides; D000068717:Glatiramer Acetate; D007372:Interferons